In a report issued on November 17, David Steinberg from Jefferies reiterated a Buy rating on Corium (NASDAQ: CORI), with
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Glaukos (NYSE:
Today, the CEO of Ligand Pharma (NASDAQ: LGND), John L. Higgins, sold shares of LGND for $751K. Following John L.
Today, the VP Finance & CFO of Ligand Pharma (NASDAQ: LGND), Matthew Korenberg, sold shares of LGND for $935.5K. In
Today, the Chairman & CEO of United Therapeutics (NASDAQ: UTHR), Martine Rothblatt, sold shares of UTHR for $702.8K. This is
In a new note to investors on November 15, an analyst has provided a rating update for the Healthcare company,
In a report released yesterday, Ritu Baral from Cowen & Co. assigned a Buy rating to Audentes Therapeutics (NASDAQ: BOLD).